Nutraceutix, an early stage biopharmaceutical company, has engaged investor relations and strategic planning company Bibicoff & Associates to increase investment community awareness of the company.
Bibicoff will initially concentrate on developing and implementing communications strategies and programs specifically targeting the retail brokerage and investment banking communities.
Harvey Bibicoff, President and CEO of Bibicoff & Associates, stated: "This is an exciting time in the corporate life of Nutraceutix and its emergence as a developer of patented technologies and products for the nutraceutical and pharmaceutical industries. During the last year management has made acquisitions of important drug delivery technologies, filed patent applications on new technologies invented by the Nutraceutix R&D staff, greatly expanded its business development activities and has begun to divest itself of non-core operations."
He continued:"We believe that the redirection and refinements Nutraceutix has initiated during the past year have served to strengthen its core operating competencies and intelligently refine its sales and marketing focus. We are optimistic that Wall Street will appreciate the company's re-engineered business model and future outlook, and thus reward the Company with significant market support."
David T. Howard, president and CEO of Nutraceutix, said: "Through our relationships with leading pharmaceutical companies and with our planned 2002 product expansion initiatives, Nutraceutix is ideally positioned to leverage its intellectual property estate, industry knowledge and marketing alliances both domestically and abroad. Consequently, we look forward to working with Bibicoff & Associates in communicating the company's new direction and growth strategies to our valued shareholders and to the investment banking community."
Based in Redmond, Washington, Nutraceutix is a biopharmaceutical company, leveraging specialised knowledge, proprietary & patented products and technologies, such as LiveBac probiotics, Cryotableting, and the three patented CDT Controlled Delivery Technology platforms, to introduce distinctive and novel OTC products, prescription drugs and dietary supplements.